Intensive Care Medicine

, Volume 33, Issue 9, pp 1571–1579

Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study

  • Michael Joannidis
  • Jordan Kountchev
  • Markus Rauchenzauner
  • Nicola Schusterschitz
  • Hanno Ulmer
  • Andreas Mayr
  • Romuald Bellmann
Original

DOI: 10.1007/s00134-007-0719-7

Cite this article as:
Joannidis, M., Kountchev, J., Rauchenzauner, M. et al. Intensive Care Med (2007) 33: 1571. doi:10.1007/s00134-007-0719-7
  • 451 Downloads

Abstract

Objective

The purpose of this study was to evaluate the efficacy and safety of the low molecular weight heparin enoxaparin as anticoagulant in continuous veno-venous hemofiltration (CVVH) compared with unfractionated heparin.

Design

Prospective randomized controlled crossover study.

Setting

Medical and Surgical Intensive Care Unit of a University Hospital.

Patients

Forty consecutive adult medical and surgical ICU patients with normal anticoagulation parameters requiring CVVH.

Intervention

CVVH was performed with pre-filter fluid replacement at 2500 ml/h and blood flow rates of 180 ml/min. Heparin-treated patients received an initial pre-filter bolus of 30 IU/kg and a maintenance infusion at 7 units/kg h−1, titrated to achieve a systemic activated partial thromboplastin time (aPTT) of 40–45 s. Enoxaparin-treated patients received an initial pre-filter bolus of 0.15 mg/kg and a maintenance infusion starting at 0.05 mg/kg h−1, which was subsequently adjusted to maintain systemic anti-factor Xa activity (anti-Xa) at 0.25–0.30 IU/ml. Each patient received both regimens in a crossover design. Maximum treatment duration for each set was 72 h.

Results

Patients included had a mean APACHE II score of 22 (10–35). Thirty-seven patients completed both study arms. Mean filter life span was 21.7 h (± 16.9 h) for heparin and 30.6 h (± 25.3) for enoxaparin (p = 0.017, ANOVA for repeated measures). One major bleeding episode occurred during heparin as well as during enoxaparin treatment. Cost analysis showed average daily costs of 270 and 240 € for heparin and enoxaparin, respectively.

Conclusion

Enoxaparin can be safely used for anticoagulation during CVVH resulting in higher filter lifespan compared with unfractionated heparin.

Keywords

anticoagulation CVVH renal replacement therapy costs safety unfractionated heparin low molecular weight heparin filter life span Enoxaparin 

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Michael Joannidis
    • 1
  • Jordan Kountchev
    • 1
  • Markus Rauchenzauner
    • 1
  • Nicola Schusterschitz
    • 1
  • Hanno Ulmer
    • 2
  • Andreas Mayr
    • 3
  • Romuald Bellmann
    • 1
  1. 1.Division of General Internal Medicine, Department of Internal Medicine, Medical Intensive Care UnitMedical University InnsbruckInnsbruckAustria
  2. 2.Department of Medical Statistics, Informatics and Health EconomicsMedical University InnsbruckInnsbruckAustria
  3. 3.Department of Anesthesia and Critical Care MedicineMedical University InnsbruckInnsbruckAustria

Personalised recommendations